A study on the combination therapy of HSP90 inhibitors for colorectal cancer indicated that HSP90 can enhance immunotherapy through the Fas/FasL axis between cancer cells and T cells, HSP90 was able to improve immunotherapy through cancer cells and the T cell Fas/FasL axis [35]. The gene discussed is FASLG; the disease is cancer.